PubMed HealthSearch

PubMed · 3154413

Sensitization effect.

Abstract

1. Approximately 15% of males were sensitized by transfusions before their first grafts. About 40% of females were sensitized by pregnancies and transfusions. Following graft rejection about 60% of males and females were sensitized. 2. The one-year graft survival of nonsensitized and sensitized patients differed by 4 to 7% in first, second, and third transplants. The difference developed very early and even on the first day after transplantation. 3. Patients with a high peak level of antibody tended to have lower graft survival, particularly in regrafted patients. If the peak level of antibody was under 50% panel reactive antibody, graft survival was the same as in patients who never had preformed cytotoxins. 4. Parous women without transfusions and no preformed antibodies had a 49% one-year graft survival with no transfusions and 71% with transfusions. Similar findings were noted in regrafted parous women and those with preformed antibodies. Thus, pregnancy exerted a deleterious effect which was reversed by transfusions. 5. Between the best and worst HLA-A,B,DR match there was a 19% difference in one-year graft survival for nonsensitized patients, and a 26% difference in patients sensitized to more than 50% of the panel. A similar difference was noted in regrafted patients for sensitized and highly sensitized patients. 6. Transfusions had a greater effect on the outcome of transplantation than the state of sensitization. First cadaver donor patients without transfusions and without antibodies had a one-year graft survival of 57% whereas patients with more than 50% panel reactive antibodies had graft survival of 59 to 71%.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Y Iwaki, P I Terasaki. 1986. Sensitization effect.. https://pubmed.ncbi.nlm.nih.gov/3154413/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Reduction of TNF-alpha release and clinical effects of the first injection of OKT3].

In order to prevent the adverse effects of a first OKT3 injection in renal transplant recipients, we administered polyclonal antilymphocyte globulins (ATG Fresenius, 4 mg/kg/j) for 3 days before OKT3 injection. Compared with a historical group of 5 patients who did not receive ATG pretreatment before OKT3 injection, the patients who were pretreated by ATG had a significantly lower absolute number of circulating lymphocytes before the first OKT3 injection (363 +/- 107 vs 1,230 +/- 80/mm3, P < 0.001), a lower raise in plasma TNF-alpha level 2 hours after OKT3 injection (178 +/- 42 vs 735 +/- 127 pg/ml, P < 0.005) and a significant decrease in frequency and intensity of clinical symptoms, mainly chills, dyspnea, and headaches. However, fever and peak creatinine level were similar in both groups. A 80 percent success rate of crisis treatment was achieved in both groups and there was no increase in infectious complications. In conclusion, pretreatment with ATG induces a lymphocyte depletion, and decreases the amounts of TNF-alpha released as well as the side-effects of a first OKT3 injection.

Antilymphocyte Serum

Evaluation of flowcytometric crossmatching in renal allograft recipients.

Forty-four cadaver renal allograft recipients who had flowcytometric cross-match (FCXM) testing and sequential quadruple immunosuppression were studied with respect to the number of rejection episodes and the functional viability of the graft in the first year after transplantation. Fourteen of these patients had antibodies to donor T cells by FCXM. All were negative by conventional crossmatch. Multiple-regression analysis with HLA mismatches, panel-reactive antibody (PRA) percentage, flowcytometric channel shifts and transplant number as independent variables revealed that transplant number and high PRA (> 50%) impacted (p < 0.05) on serum creatinine at 1 month and 1 year, and graft survival at 1 year. In first transplants, a positive FCXM had no impact on 1-year graft survival rates; however, in retransplants, a positive FCXM and/or high PRA had a significant negative impact on 1-year graft survival. This study indicates that the FCXM should be utilized for retransplant patients, and in patients with a high PRA, in an attempt to improve graft survival for these high-risk recipients.

Antilymphocyte Serum